Results 81 to 90 of about 5,939 (158)

Dupilumab Combined With House Dust Mite Allergen Immunotherapy for Atopic Dermatitis: A Systematic Review and Meta‐Analysis

Clinical and Translational Allergy, Volume 16, Issue 8, August 2026.
ABSTRACT Background Dupilumab is effective for moderate‐to‐severe atopic dermatitis (AD), but sustained disease control after treatment discontinuation remains challenging. House dust mite allergen immunotherapy (HDM‐AIT) may provide disease‐modifying effects in sensitized patients, but the added value of combining HDM‐AIT with dupilumab remains ...
Jiale Lian, Ling Ren, Jing Liang, Shuping Guo   +3 more
wiley   +1 more source

Oral lichenoid lesions in CTLA‐4 haploinsufficiency: Targeting IFN‐γ‐driven mucosal immunopathology

Journal of the European Academy of Dermatology and Venereology, EarlyView.
Chen Wang, Laurie Brenchley, Teresa Greenwell‐Wild, Vasileios Ionas Theofilou, Timothy G. Myers, Chi A. Ma, Katherine Howe, Stefania Pittaluga, Steven M. Holland, Niki M. Moutsopoulos, David Fraser, Gulbu Uzel   +11 more
wiley   +1 more source

The Burden of Viral Respiratory Infections in Immunosuppressed Inflammatory Bowel Disease Patients

JGH Open, Volume 10, Issue 8, August 2026.
ABSTRACT Background and Aim Due to the increasing immunosuppressant use in inflammatory bowel disease (IBD) and the risk of serious infections, this study investigates the prevalence and risk factors of respiratory pathogen detection in this population to improve patient care.
D. Huynh, E. Khoo, A. Shanmuga Anandan, J. Begun   +3 more
wiley   +1 more source

Application of Systems Genetics to Investigate Molecular Pathology of Early‐Onset Colorectal Cancer

Chemical Biology &Drug Design, Volume 108, Issue 2, August 2026.
Early‐onset colorectal cancer (EOCRC) presents a complex molecular landscape that requires integrated multi‐omics approaches. This article reviews current applications of systems genetics in EOCRC research and provides a step‐by‐step protocol for network‐based analyses featuring PIK3CA to demonstrate practical application for researchers of all levels.
Minjae J. Kim, Sydney L. Carr, Vishnutheertha Kulkarni, Mary‐Louise Manchadi   +3 more
wiley   +1 more source

Amenorrhea in an Adolescent Female as a Rare Adverse Event of Upadacitinib Treatment for Atopic Dermatitis

Patient Preference and Adherence
Yan Teng, Yi Tang, Yibin Fan, Xiaohua Tao,* Yang Ding* Center for Plastic & Reconstructive Surgery, Department of Dermatology, Zhejiang Provincial People’s Hospital, Affiliated People’s Hospital of Hangzhou Medical College, Hangzhou, People’s ...
Teng Y, Tang Y, Fan Y, Tao X, Ding Y
doaj  

Upadacitinib for the treatment of radiographic axial spondyloarthritis — case series and review of the literature

Drugs in Context
Upadacitinib is a Janus kinase (JAK) inhibitor approved for the treatment of different rheumatic diseases, including axial spondyloarthritis (axSpA).
Giuseppe Lopalco, Arianna D’Antonio, Maria Sole Chimenti, Florenzo Iannone   +3 more
doaj   +1 more source

S3‐Leitlinie Diagnostik und Therapie der Alopecia areata – Teil 2: Therapie, psychosoziale und kosmetische Unterstützung

JDDG: Journal der Deutschen Dermatologischen Gesellschaft, Volume 24, Issue 8, Page 1155-1179, August 2026.
Zusammenfassung In diesem zweiten Teil der S3‐Leitlinie zur Diagnostik und Therapie der Alopecia areata (AA) stellen wir die zentralen Inhalte und Empfehlungen zur topischen und systemischen Therapie, zur Lebensqualität und zu Unterstützungsangeboten vor.
Ulrike Blume‐Peytavi, Andria Constantinou, Tsenka Tomova‐Simitchieva, Adrian Tanew, Michael Sticherling, Hermann Girschick, Annika Vogt, Uwe Schwichtenberg, Uwe Gieler, André Märtens, Kerstin Zienert, Claudia Stenders, Ricardo Niklas Werner, Doris Wilborn   +13 more
wiley   +1 more source

S3 guideline diagnostics and therapy in alopecia areata – Part 2: Therapy, psychosocial and cosmetic support

JDDG: Journal der Deutschen Dermatologischen Gesellschaft, Volume 24, Issue 8, Page e1155-e1177, August 2026.
Summary This second part of the S3 guideline on the diagnosis and treatment of alopecia areata (AA), presents key recommendations on topical and systemic therapy, quality of life and support services. The first part of the guideline, published separately, covers the definition and content of epidemiology and diagnosis as well as comorbidities, risk and
Ulrike Blume‐Peytavi, Andria Constantinou, Tsenka Tomova‐Simitchieva, Adrian Tanew, Michael Sticherling, Hermann Girschick, Annika Vogt, Uwe Schwichtenberg, Uwe Gieler, André Märtens, Kerstin Zienert, Claudia Stenders, Ricardo Niklas Werner, Doris Wilborn   +13 more
wiley   +1 more source

Long-term sustainability of response to upadacitinib among patients with active rheumatoid arthritis refractory to biological treatments: results up to 5 years from SELECT-BEYOND

RMD Open
Objective To evaluate the long-term sustainability of response to the Janus kinase inhibitor upadacitinib among patients with rheumatoid arthritis and an inadequate response or intolerance to biological disease-modifying antirheumatic drugs (bDMARD-IR ...
Ronald F van Vollenhoven, Roy Fleischmann, Stephen Hall, Yanna Song, Sebastian Meerwein, Alvin F Wells, Oishi Tanjinatus   +6 more
doaj   +1 more source

Cutaneous T‐cell lymphomas and dupilumab for atopic dermatitis: A systematic review and expert consensus

Journal of the European Academy of Dermatology and Venereology, Volume 40, Issue 8, Page 1344-1358, August 2026.
Systematic review (51 studies; 547 patients) indicates dupilumab may unmask/worsen CTCL (mainly MF/SS). A French Delphi consensus recommends rigorous diagnostic workup, avoiding dupilumab in confirmed CTCL, discontinuing upon diagnosis, and favouring methotrexate or phototherapy.
Florent Amatore, Madeleine Neildez, Adèle de Masson, Maxime Battistella, Marie Tauber, Saskia Ingen‐Housz‐Oro, Catherine Droitcourt, Delphine Staumont‐Sallé, Marie Beylot‐Barry   +8 more
wiley   +1 more source